Misk Pharma proudly unveils Oxsedo® 200 mg, an advanced erectile dysfunction (ED) therapy powered by Udenafil and launched through a strategic partnership with the Korean pharmaceutical leader Dong-A Pharmaceutical.

A Smarter Evolution in ED Therapy

Erectile dysfunction is a prevalent and clinically important men’s health condition that can significantly affect quality of life. It impacts millions of men globally, with a notably high prevalence across MENA countries, including Jordan, particularly among men over the age of 40.

This widespread prevalence underscores the importance of providing effective, reliable, and sustainable treatment options.

In a therapeutic area that has seen limited innovation for more than two decades, Oxsedo® represents a meaningful evolution within the PDE-5 inhibitor class.

Udenafil is distinguished by its rapid onset of action, sustained therapeutic window, and improved tolerability, delivering a balanced and patient-centric treatment experience.

Designed to provide reliable efficacy with fewer treatment-limiting side effects, Oxsedo® supports timely responsiveness, prolonged confidence during intimacy, and improved treatment adherence, aligning closely with real-world patient and physician expectations.

Manufactured in accordance with the highest international quality and safety standards, Oxsedo® 200 mg equips healthcare professionals with a next-generation option for ED management.

Misk Pharma is preparing to expand Oxsedo® across key MENA markets and establish it as a leading regional reference in modern erectile dysfunction management.